IBER.U (Ibere Pharmaceuticals) FCF Margin % : 0.00% (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ibere Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2022 was $-0.09 Mil. Ibere Pharmaceuticals's Revenue for the three months ended in Sep. 2022 was $0.00 Mil. Therefore, Ibere Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2022 was 0.00%.

As of today, Ibere Pharmaceuticals's current FCF Yield % is -0.39%.

The historical rank and industry rank for Ibere Pharmaceuticals's FCF Margin % or its related term are showing as below:

IBER.U's FCF Margin % is not ranked ^*
in the Diversified Financial Services industry.
Industry Median: -0.12
* Ranked among companies with meaningful FCF Margin % only.

Ibere Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Ibere Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals FCF Margin % Chart

Ibere Pharmaceuticals Annual Data

Trend

Dec20

Dec21

FCF Margin %

Ibere Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
FCF Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Ibere Pharmaceuticals's FCF Margin %

For the Shell Companies subindustry, Ibere Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ibere Pharmaceuticals's FCF Margin % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Ibere Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ibere Pharmaceuticals's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Ibere Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ibere Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-0.869	/	0
	=	%

Ibere Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2022 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	-0.089	/	0
	=	%

Ibere Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Ibere Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ibere Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103

Website

https://www.iberepharma.com

Ibere Pharmaceuticals is a blank check company.

Executives

Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie	director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes	director, 10 percent owner, officer: Chief Operating Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray	director, 10 percent owner, officer: Chief Financial Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc	10 percent owner	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines

From GuruFocus

Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 05-28-2021

Ibere Pharmaceuticals Announces Closing of $138,000,000 Initial Public Offering

By PRNewswire PRNewswire • 03-03-2021